ROIVANT SCIENCES LTD (ROIV) Stock News
NASDAQ:ROIV - Nasdaq - BMG762791017 - Common Stock - Currency: USD
ROIV Latest News, Press Relases and Analysis
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they...
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -37.50% and 88.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: XAIR
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth...
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
On May 28, H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Roivant Sciences Ltd. (NASDAQ:ROIV) while keeping the price target the same at $18. The reiteration comes after the company appointed the current President and COO of Roivant, Dr. Eric Venker as CEO of Immunovant. Roivant Sciences Ltd. (NASDAQ:ROIV) is the founding parent […]
UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating
On May 28, UBS lowered the firm’s price target on Westlake Corporation (NYSE:WLK) from $118 to $101, while keeping a Buy rating on the stock. The adjustment reflects the near-term challenges for the company’s Performance and Essential Materials (PEM) Segment. The company reported its fiscal first quarter results for 2025 on May 2. The company […]
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results from the Phase 2 TRANQUILITY trial of Pacibekitug. Analyst Chen noted the results from the Phase 2 TRANQUILITY trial showed a significant reduction […]
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.11% and 167.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: GOSS
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
BASEL, Switzerland and LONDON and NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference...
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -25% and 28.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CDXS
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -7.14% and 5.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: LQDA
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
Style Box ETF report for RFG
Roivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside Potential
We recently published an article titled Billionaire David Einhorn’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against David Einhorn’s other stock picks with huge upside potential. David Einhorn is a widely renowned hedge fund manager who co-founded Greenlight Capital in 1996. The billionaire […]
Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among former […]
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
The company is getting a new chief executive and a new chief financial officer amid sweeping changes.
Mentions: IMVT
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D....
Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President Donald […]
Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In
We recently published a list of 10 Best Low Priced Growth Stocks To Invest In. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against other best low priced growth stocks. Low priced stocks usually fall under the small to mid-cap size category. This growth criteria, often […]
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy?
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
The companies reported positive results for their lead asset in patients with two rare diseases.
Mentions: IMVT
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose...
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Mentions: ABUS